Company / strategic investorRegistered location :4056 Basel

Novartis AGDeclared Swiss shareholdings

Novartis AG: 3 Swiss companies with a declared holding, including Novartis AG, Molecular Partners AG, EvoNext Holdings SA. Latest filing: 25.03.2025.

Disclosure tracking · company alerts with Pro

Estimated value (CHF): …
Swiss companies held: 3
Largest position: 7,04 %; Novartis AG
12-month trend: Not determinable; 0 rate rises · 0 rate falls
Latest filing: 25.03.2025; Active since 2011

Declared Swiss portfolio

Latest declared rate per company

Sector allocation

Share of companies held

Novartis AG

7,04 %25.03.2025

Molecular Partners AG

4,86 %31.08.2022

EvoNext Holdings SA

2,97 %13.04.2012

How to read these figures?

Rates come from the 51 official filings published by SIX Exchange Regulation. A filing is only required when a threshold is crossed (3, 5, 10, 15, 20, 25, 33⅓, 50, 66⅔%): the actual position may have changed since.

Estimated value = shares held per the latest filing × latest CHF closing price. It is an indicative order of magnitude: the position may have changed without a new threshold being crossed, and holdings without a share count or a CHF price are not valued. Each company's mini-chart traces the successive declared rates.

This profile shows only what the declarant published. No external data is added to it.

Group structure

Shareholding disclosures are often filed jointly by several entities of the same group. The registry links them together: "Controls" lists the group entities declared alongside this shareholder, "Controlled by" the head entities. The figure is the number of joint disclosures, followed by the date of the most recent one.

Show group structure1 controlled by · 10 controls

Controlled by

Group entities that file jointly with this shareholder as its head.

Novartis1 · 22.02.2025

Controls

Group entities linked to this shareholder in joint disclosures.

Novartis Holding AG37 · 31.01.2025
Novartis Investment Ltd23 · 19.02.2024
Novartis Corporation20 · 19.03.2024
Novartis Forschungsstiftung17 · 25.03.2025
Novartis Stiftung für Kaderausbildung17 · 25.03.2025
Novartis Stiftung für Mensch und Umwelt17 · 25.03.2025
Novartis-Mitarbeiterbeteiligungsstiftung17 · 25.03.2025
Novartis Investments Sàrl14 · 25.08.2017
Novartis Pharma AG2 · 31.08.2022
Novartis Bioventures Ltd2 · 13.04.2012

This mapping reflects observed disclosures; it does not necessarily indicate permanent legal control.

Disclosure behaviour

Upward and downward threshold crossings show direction, without measuring daily trades below legal thresholds.

90 days · Upward crossings

visible history: 48

90 days · Downward crossings

visible history: 0

First disclosure: 31.08.2011Last disclosure: 25.03.2025

Nature of disclosed positions

Derivatives, sale positions or lending may indicate a more complex strategy than a long equity holding.

Equity holdings

Rights / derivatives

Sale positions

518

Declared Swiss portfolio

Sector allocation

Group structure

Controlled by

Controls

Disclosure behaviour

Nature of disclosed positions

Latest shareholding disclosures

Follow Novartis AG’s disclosures

Management purchases in this portfolio

Common questions

Explore further

Recent insider purchases

Insider barometer